Can payment models for gene therapies evolve fast enough to keep up?
The cell and gene therapy revolution is growing rapidly. That may be a problem for payers and our current healthcare system, which is incentivized by short-term returns and immediate cost avoidance rather than long- term benefits of improved patient health.
Gene therapy is revolutionizing healthcare, but can we revolutionize payment models in time to keep up?
